Symbols

XTLB

Xtl Biopharmaceuticals·NASDAQ

--(--)

XTLB Profile

Xtl Biopharmaceuticals Ltd.

A biopharmaceutical company that developing drugs for the treatment of autoimmune diseases

Industry

Pharmaceutical

Established Date

03/09/1993

Listing Date

07/15/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.xtlbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

26 Ben-Gurion St. Ramat Gan 5112001 Israel

Business

Engaged in the acquisition and research and development of pharmaceutical products.

Introduction

Xtl Biopharmaceuticals Ltd., established under the laws of Israel on March 9, 1993, is a biopharmaceutical company focused on acquiring and developing medicines to meet unmet medical needs, especially for diseases such as multiple myeloma (MM), schizophrenia and hepatitis C. Through its subsidiary InterCure, the company develops and sells home treatment devices for non-drug and non-invasive treatment of various diseases, including hypertension, heart failure, insomnia and mental stress. In addition, Xtl, through its wholly-owned subsidiary The Social Proxy, engages in intellectual property activities related to agency and data collection. The company holds a license from Yeda for hCDR1, a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). Since its inception, Xtl has focused on developing technologies and drug candidates, acquiring compounds in the preclinical and clinical stages, and raising capital, but has yet to achieve drug sales.